Modulation of NKp30- and NKp46-Mediated Natural Killer Cell Responses by Poxviral Hemagglutinin

Direct Action of Type I IFN on NK Cells Is Required for Their Activation in Response to Vaccinia Viral Infection In Vivo

(2014) J. Martinez et al.   JOURNAL OF IMMUNOLOGY

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy

(2009) Andrea Worschech et al.   BMC GENOMICS

The immunologic aspects of poxvirus oncolytic therapy

(2009) Andrea Worschech et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

(2009) Cameron S. Brandt et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase

(2009) M. Jarahian et al.   JOURNAL OF VIROLOGY

Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68

(2009) Y. A. Yu et al.   MOLECULAR CANCER THERAPEUTICS

The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation

(2009) Qian Zhang et al.   MOLECULAR GENETICS AND GENOMICS

Expression of the A56 and K2 Proteins Is Sufficient To Inhibit Vaccinia Virus Entry and Cell Fusion

(2008) T. R. Wagenaar et al.   JOURNAL OF VIROLOGY

A Role for NKG2D in NK Cell–Mediated Resistance to Poxvirus Disease

(2008) Min Fang et al.   PLoS Pathogens

The vaccinia virus fusion inhibitor proteins SPI-3 (K2) and HA (A56) expressed by infected cells reduce the entry of superinfecting virus

(2008) Peter C. Turner et al.   VIROLOGY